Pay in 4 interest-free payments of $5.07 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
This editorial breakdown covers the mechanics of the pricing model, not a quote verify live numbers on the brand's own site
[4] Wilding JP
What is the ICD10 code for removal of a Central Venous Catheter (CVC) in a patient undergoing renal recovery?
Selective biodistribution in inflamed tissues due to enhanced permeability and the resultant lower effective dose and longer duration of drug action leading to decreased dose frequency are a recurring theme with nano-medicines in RA models with less systemic side-effects [28]
Apitegromab: Phase 3 SAPPHIRE in SMA# The Phase 3 SAPPHIRE trial represents the most advanced clinical success for any myostatin-targeted therapy: 188 patients aged 2-21 with Type 2 or 3 SMA, all receiving background SMN-targeted treatment Primary endpoint met : Clinically meaningful improvement on HFMSE (Hammersmith Functional Motor Scale Expanded) versus placebo (p=0.0192), with a mean difference of 1.8 points Functional responders : 30.4% of apitegromab patients achieved 3 or more point HFMSE improvement versus 12.5% placebo Upper limb function : Consistent improvement measured by RULM (Revised Upper Limb Module) Published in The Lancet Neurology This is notable because it overcomes the historical "mass-function disconnect" that plagued earlier myostatin inhibitors -- apitegromab improved actual motor function, not just muscle mass
US$ 24.98
US$ 23.92
US$ 29.54
